What is a cheaper alternative to Remeron (mirtazapine) for a hospice patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cheaper Alternatives to Remeron (Mirtazapine) for Hospice Patients

Generic mirtazapine is already one of the most cost-effective antidepressants available at $5-20 per month, making it difficult to find a meaningfully cheaper alternative while maintaining similar benefits for hospice patients. 1

Cost Comparison of Antidepressant Options

If cost reduction is absolutely necessary, consider these alternatives based on pricing data:

  • Amitriptyline: $5-12/month (comparable or slightly cheaper than generic mirtazapine) 1
  • Trazodone: $4-10/month (cheapest option) 1
  • Citalopram: $4/month 1
  • Nortriptyline: $4-12/month 1
  • Generic mirtazapine: $5-20/month for comparison 1

Critical Considerations for Hospice Patients

However, switching away from mirtazapine in hospice care may be clinically inappropriate because mirtazapine offers unique benefits specifically valuable at end of life:

  • Appetite stimulation and weight gain: Mirtazapine addresses depression-related appetite loss, which is particularly beneficial in hospice patients with poor nutritional intake 2, 3
  • Sleep improvement: The sedative effects help with insomnia commonly seen in end-of-life care 2
  • Anxiolytic properties: Reduces anxiety symptoms without requiring additional medications 4, 5
  • Rapid onset: Shows antidepressant effects as early as 1 week, important given limited life expectancy 6, 4

If Cost-Driven Switch Is Mandatory

Option 1: Trazodone ($4-10/month)

  • Cheapest alternative with some sedative and antidepressant properties 1
  • Provides sleep benefits similar to mirtazapine 1
  • Caveat: Less effective than mirtazapine for depression in comparative trials 6, 4
  • Dosing: 50-400 mg daily 1

Option 2: Citalopram ($4/month)

  • Very low cost SSRI option 1
  • Considered safe in older adults and preferred first-line agent 1
  • Major drawbacks for hospice:
    • No appetite stimulation (may worsen anorexia)
    • No sedative benefit for sleep
    • Can cause QTc prolongation 1, 2
    • May take longer to show effect than mirtazapine 4
  • Dosing: 20-40 mg daily 1

Option 3: Amitriptyline ($5-12/month)

  • Comparable cost to generic mirtazapine 1
  • Provides sedation and appetite stimulation 1
  • Critical warning: Tricyclic antidepressants like amitriptyline should be avoided in hospice patients due to:
    • Significant anticholinergic effects (confusion, urinary retention, constipation) 1
    • Orthostatic hypotension and fall risk 1, 3
    • Potential worsening of cardiac function 1
    • Considered potentially inappropriate in elderly per Beers Criteria 1

Clinical Recommendation Algorithm

Step 1: Verify the patient is receiving generic mirtazapine (not brand-name Remeron), as generic costs $5-20/month versus brand at $160-170/month 1

Step 2: If generic mirtazapine is already being used and cost remains prohibitive:

  • First choice: Switch to trazodone if sedation/sleep is the primary benefit needed 1
  • Second choice: Switch to citalopram only if depression is the sole indication and patient has adequate appetite/sleep 1

Step 3: Avoid tricyclic antidepressants (amitriptyline, nortriptyline) in hospice patients despite low cost due to safety concerns 1, 3

Common Pitfall to Avoid

Do not sacrifice quality of life for minimal cost savings in hospice care. The difference between mirtazapine at $5-20/month and alternatives at $4-12/month is negligible ($1-8/month savings), while the clinical benefits of mirtazapine for appetite, sleep, and rapid mood improvement are substantial and difficult to replicate with cheaper alternatives 1, 7. Mirtazapine has been specifically described as a "designer drug for palliative medicine" due to its unique benefit profile 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Mirtazapine and Escitalopram Combination Therapy for Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Optimizing Mirtazapine Dose for Persistent Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Mirtazepine: heir apparent to amitriptyline?

The American journal of hospice & palliative care, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.